Mineralys Therapeutics (MLYS) Total Current Liabilities (2022 - 2026)

Mineralys Therapeutics has disclosed Total Current Liabilities across 5 years of filings, most recently posting $14.7 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $14.7 million, up 9.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.7 million (up 9.95% YoY), and the FY2025 annual result was $15.1 million, up 3.19% from the prior year.
• Total Current Liabilities came in at $14.7 million for Q1 2026 at Mineralys Therapeutics, down from $15.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.3 million in Q3 2024 to a low of $6.2 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $14.7 million (2024), against an average of $16.5 million.
• Across the five-year window, Total Current Liabilities surged 357.5% in 2024 and tumbled 30.3% in 2025, its largest moves.
• Mineralys Therapeutics' Total Current Liabilities stood at $8.1 million in 2022, then rose by 29.94% to $10.5 million in 2023, then soared by 39.73% to $14.6 million in 2024, then gained by 3.19% to $15.1 million in 2025, then retreated by 2.61% to $14.7 million in 2026.
• The last three Total Current Liabilities figures came in at $14.7 million (Q1 2026), $15.1 million (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.